Clinical Trials Browser

Phase 1/2 × OTHER × tafasitamab × Clear all

NCT05455697 2025-12-18

Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma

Phase 1/2 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT06029309 2025-10-06

ZANU-TAFA

Phase 1/2 Recruiting

Lymphoma, Mantle-Cell